Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Boehringer Ingelheim
Mallinckrodt
Dow
McKesson

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,775,838

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,775,838 protect, and when does it expire?

Patent 9,775,838 protects NARCAN and is included in one NDA.

This patent has twenty patent family members in fourteen countries.

Summary for Patent: 9,775,838
Title:Nasal drug products and methods of their use
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
Inventor(s): Keegan; Fintan (Dublin, IE), Bell; Robert Gerard (Clearwater, FL), Crystal; Roger (Santa Monica, CA), Weiss; Michael Brenner (New York, NY)
Assignee: ADAPT PHARMA LIMITED (Dublin, IE) OPIANT PHARMACEUTICALS (Santa Monica, CA)
Application Number:15/589,090
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,775,838
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device;

Drugs Protected by US Patent 9,775,838

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Adapt NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411-001 Nov 18, 2015 RX Yes Yes   Start Trial   Start Trial USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Dow
Baxter
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.